胎盘生长因子抑制靶向肺血管生成并代表小鼠肝肺综合征的一种治疗策略
研究采用小鼠胆总管结扎(CBDL)建立肝肺综合征(HPS)模型,观察肺血管生成与炎症的动态变化。结果显示HPS小鼠肺内PlGF产生增加,预防性和治疗性抗PlGF抗体治疗均能减少肺内分流、改善气体交换并减轻肺内皮功能障碍与炎症,且不影响肝脏改变。作者认为抗PlGF可能成为人类HPS有吸引力的治疗策略。
要点
- 小鼠CBDL可诱导HPS,表现为低氧血症和肺内分流,并伴肺血管生成与炎症标志物升高。
- HPS小鼠肺内PlGF产生增加,免疫荧光显示来源于肺泡II型细胞和肺巨噬细胞。
- 预防性和治疗性抗PlGF抗体治疗均减少肺内分流、改善气体交换,且不改变肝脏病变。
核心结论
- 小鼠CBDL诱导的HPS由PlGF产生介导;抗PlGF治疗通过抑制肺血管生成改善实验性HPS,作者认为可能成为人类HPS有吸引力的治疗策略。
研究设计与样本
- 研究采用小鼠胆总管结扎(CBDL)建立HPS模型,并验证该模型;同时检测人HPS患者血清。
- 研究观察HPS发展过程中肺血管生成和炎症的动态变化,并评估抗PlGF抗体治疗的效果。
主要发现
- CBDL小鼠在肝纤维化背景下出现低氧血症和肺内分流,肺部促血管生成和炎症标志物水平升高,人HPS患者血清中亦得到证实。
- 免疫荧光显示HPS小鼠肺内增加的PlGF产生来源于肺泡II型细胞和肺巨噬细胞。
- 血管腐蚀铸型显微镜显示CBDL小鼠存在血管形成功能障碍。
- 预防性和治疗性抗PlGF抗体治疗均显著减少肺内分流并改善气体交换。
- 抗PlGF治疗在体内和体外均减轻内皮细胞功能障碍,并伴随肺部炎症减轻,且不影响肝脏改变。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Hepatopulmonary syndrome (HPS) is a severe complication of cirrhosis with increased risk of mortality. Pulmonary microvascular alterations are key features of HPS; but underlying mechanisms are incompletely understood, and studies on HPS are limited to rats. Placental growth factor (PlGF), a proangiogenic molecule that is selectively involved in pathological angiogenesis, may play an important role in HPS development; however, its role has never been investigated. In this study, we validated an HPS model by common bile duct ligation (CBDL) in mice, investigated the kinetic changes in pulmonary angiogenesis and inflammation during HPS development, and provide evidence for a novel therapeutic strategy by targeting pathological angiogenesis. Mice with CBDL developed hypoxemia and intrapulmonary shunting on a background of liver fibrosis. Pulmonary alterations included increased levels of proangiogenic and inflammatory markers, which was confirmed in serum of human HPS patients. Increased PlGF production in HPS mice originated from alveolar type II cells and lung macrophages, as demonstrated by immunofluorescent staining. Dysfunctional vessel formation in CBDL mice was visualized by microscopy on vascular corrosion casts. Both prophylactic and therapeutic anti-PlGF (αPlGF) antibody treatment impeded HPS development, as demonstrated by significantly less intrapulmonary shunting and improved gas exchange. αPlGF treatment decreased endothelial cell dysfunction in vivo and in vitro and was accompanied by reduced pulmonary inflammation. Importantly, αPlGF therapy did not affect liver alterations, supporting αPlGF's ability to directly target the pulmonary compartment. CONCLUSION: CBDL in mice induces HPS, which is mediated by PlGF production; αPlGF treatment improves experimental HPS by counteracting pulmonary angiogenesis and might be an attractive therapeutic strategy for human HPS. (Hepatology 2017).
引用
- Raevens S, Geerts A, Paridaens A, et al. Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice. Hepatology. 2018. PMID: 29023811. doi:10.1002/hep.29579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。